N0-923 TDS IN PATIENTS WITH PARKINSON'S DISEASE

N0-923 帕金森病患者的 TDS

• 批准号: 6113193
• 负责人: JORGE L JUNCOS
• 金额: $ 3.83万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6113193
• 关键词: Parkinson's disease; antiparkinson drugs; clinical research; clinical trials; combination chemotherapy; dihydroxyphenylalanine; dopamine agonists; dosage; human subject; human therapy evaluation; nervous system disorder chemotherapy; placebos; transdermal drug delivery

This is a randomized, parallel, double-blind, placebo-controlled study to examine the use of a skin patch delivery system to deliver a new investigational drug (N-0923) to treat the signs and symptoms of Parkinson disease. The study will determine the safest and most effective dose when used with levodopa/carbidopa, and whether this new drug will allow for a reduction in the daily dose of levodopa/carbidopa.

这是一项随机、平行、双盲、安慰剂对照研究 检查使用皮肤贴片输送系统来输送新的 用于治疗帕金森病体征和症状的研究药物 (N-0923) 疾病。该研究将确定最安全、最有效的剂量 与左旋多巴/卡比多巴一起使用时，以及这种新药是否允许 减少左旋多巴/卡比多巴的每日剂量。